


# Do Low Concentrations of Hexavalent Chromium in Drinking Water Pose a Cancer Hazard?

## Results of ACC's Cr(VI) Mode of Action Study



**Deborah Proctor**

Chad Thompson, Mark Harris, Mina Suh, Laurie Haws,  
Chris Kirman and Sean Hays

**ToxStrategies, Inc. and Summit Toxicology**

November 2012

*Research Project funded by the Cr 6 Panel of the American Chemistry Council*

ToxStrategies

# Presentation Overview

- Background regarding Cr(VI) toxicology and the Mode of Action (MOA) Research Project
- Research findings that inform the risk assessment for relevant drinking water exposure (i.e., by humans at low levels)
- How kinetic models<sup>1</sup> and “mode of action” data are used in cancer risk assessment to set safe levels
- Calculation of Drinking Water Equivalent Level (DWEL) protective of intestinal cancer



# National Toxicology Program (NTP) Study Results for Cr(VI) and Cr(III)

## NTP Cr(VI) drinking water study

- Mice and rats consuming 5,000 – 180,000  $\mu\text{g/L}$  (ppb) Cr(VI) as sodium dichromate dihydrate (SDD)
- Rare tumors appeared late in the study
  - Mice: adenomas and carcinomas of small intestines
  - Rats: squamous cell carcinoma in oral cavity



B6C3F1 mouse



F344/N rat


## NTP Cr(III) drinking water study

- No significant effects observed in either species

# Cr(VI) MOA Research Project Background

- The Cr(VI) MOA research project was developed using EPA Guidance
- Provides information as to why tumors occurred in rodents
- Provides information on the differences between rodents and humans with regard to internal dose
- Develops the models and data needed to do a State-of-the-Art Risk Assessment

# Comparison of NTP Doses to Human Exposures







Biochemistry





Pathology



Genomics




PBPK Modeling



Risk Assessment


ToxStrategies

# Biology is Important




Tissue of the Small Intestine

# Mode of Action for Intestinal Cancer



# Stomach Reduction Kinetics



## Stomach Reduction Capacity is Exceeded At Carcinogenic Doses in Rodents




# **Oxidative Stress and Chronic Toxicity in Intestinal Villi**

# Biochemical and Genomic Responses to Oxidative Stress

- Significant decreases in reduced to oxidized glutathione in mouse duodenum and jejunum
- Activation of genomic response to oxidative stress




# Toxicity in Villus & Regeneration of New Cells in Crypt




## At High Doses:

- Expanded Crypt Area, Blunted Villi
- Damage at villi tips




# Total number of Epithelial Cells in the Duodenal Crypt (Mouse Day 90)



**Does Cr(VI) Cause DNA Mutations in the Crypt or Do Tumors Occur by Spontaneous Replication Error?**

## Toxicity and DNA Damage to Cells in the Duodenal Crypt

- Mitotic Index: Percentage of Cells Undergoing Division
- Apoptotic Index: Percent of cells undergoing apoptosis (programmed cell death)
- Micronuclei: Total number of cells with an extra smaller nucleus indicating broken chromosomes



Measured in 10 fully intact crypts per animal,  
5 animals per dose

# No Toxicity to Cells in the Duodenal Crypt (Mice Day 91)

Cr(VI) Drinking Water (mg/L)	Mitotic Index (%)		Apoptotic Index (%)		Total Number of Micronuclei
0	1.43	±1.17	0.47	±0.22	0
0.1	2.28	±1.07	1.0	±0.47	0
1	2.36	±0.684	0.5	±0.4	
5	3.08	±0.46	0.7		
20	2.46	±0.76	0.5	±0.3	
60	2.72	±0.97	0.84	±0.96	0
180	2.11	±1.09	0.67	±0.33	0

**No Effect on Normal Cell Generation or Cellular Death**

## Purple for Carcinogenic Doses

Mitotic and apoptotic indices are percent of mitotic and apoptotic cells per total cells evaluated

Data represent total number of cells evaluated in 10 fully intact crypts per animal, 5 animals per dose group

# No DNA Damage in Duodenal Crypt (Mice Day 91)

Cr(VI) Drinking Water (mg/L)	Mitotic Index (%)	Apoptotic Index (%)	Total Number of Micronuclei
0	1.43 ±1.17	0.47 ±0.22	0
0.1	2.11 ±1.09	0.67 ±0.33	0
1	2.11 ±1.09	0.67 ±0.33	0
5	3.00 ±1.50	0.67 ±0.33	0
20	2.11 ±1.09	0.67 ±0.33	0
60	2.11 ±1.09	0.67 ±0.33	0
180	2.11 ±1.09	0.67 ±0.33	0

**No Evidence of DNA damage in Target Crypt Cells with Proliferation Response**

### Purple for Carcinogenic Doses

Mitotic and apoptotic indices are percent of mitotic and apoptotic cells per total cells evaluated


Data represent total number of cells evaluated in 10 fully intact crypts per animal, 5 animals per dose group

# Mutation Analysis

- ❖ When DNA is damaged, cells die, DNA is correctly repaired, or more rarely it is repaired with an incorrect code
- ❖ If the incorrect code is in an important gene sequence (an oncogene), the cells can start to divide uncontrollably, and this is called mutagenesis
- ❖ Thus, there is an important distinction between genotoxicity (damage to DNA), and mutagenesis which is a heritable change in the DNA sequence
- ❖ We looked for a specific mutation in an oncogene (K-Ras) in mouse intestinal tissue with a very sensitive method at doses that cause hyperplasia
- ❖ K-Ras codon 12 is commonly mutated in intestinal cancers
- ❖ K-Ras codon 12 GAT mutation is also a “reporter gene” for mutations in other parts of the DNA sequence
- ❖ Mutation data, such as this, are EPA’s highest tier of data for assessing whether a chemical acts by a mutagenic MOA



## K-Ras Codon 12 GAT Mutations (Mouse Duodenum, Day 91)

- K-Ras commonly mutated in intestinal cancers
- No dose-related trend with Cr(VI) exposures
- No increase at carcinogenic doses




## K-Ras Mutations: Comparison with Benzo(a)pyrene (Mouse Duodenum, Day 91)

- K-Ras Codon 12 GAT mutations increased with BaP dose and adduct formation in mouse lung (Meng et al. 2010)
- Evidence for a Mutagenic MOA for BaP in lung
- High background rate of K-Ras mutations in mouse small intestine as compared to lung and other tissues (Mutant fraction of  $\sim 10^{-3}$  in intestine and  $\sim 10^{-6}$  in lung)



From Meng et al. 2010. *Environ Mol Mutagen* 51, 146-155

# Lack of Early DNA Damage or Mutations



## MOA Study Findings (Mice)

Significant change	Cr6 Drinking Water Concentration (mg/L)					
	0.1	1.4	5	20	60	180
Day 91 Duodenum						
Cr in duodenum	-	-	✓	✓	✓	✓
Oxidative Changes	-	-	✓	<u>✓</u>	<u>✓</u>	<u>✓</u>
Gene Changes	-	-	<u>✓</u>	<u>✓</u>	<u>✓</u>	<u>✓</u>
Villus toxicity	-	-	-	✓	<u>✓</u>	<u>✓</u>
Crypt proliferation	-	-	-	-	✓	<u>✓</u>
Crypt DNA damage	-	-	-	-	-	-
<i>K-Ras</i> mutation (Codon 12 GAT)	-	-	-	-	-	-

Underlined checks indicate significant changes at day 8 as well, Cr concentrations not measured at day 8.

## MOA Study Findings (Mice)


Significant change	Cr6 Drinking Water Concentration (mg/L)					
	0.1	1.4	5	20	60	180
Day 91 Duodenum						
Cr in duodenum	No Effect in the Low Dose Range		✓	✓	✓	✓
Oxidative Changes			✓	<u>✓</u>	<u>✓</u>	<u>✓</u>
Gene Changes			<u>✓</u>	<u>✓</u>	<u>✓</u>	<u>✓</u>
Villus toxicity			-	✓	<u>✓</u>	<u>✓</u>
Crypt proliferation			-	-	✓	<u>✓</u>
Crypt DNA damage			-	-	-	-
<i>K-Ras</i> mutation (Codon 12 GAT)			-	-	-	-

## MOA Study Findings (Mice)


Significant change	Cr6 Drinking Water Concentration (mg/L)					
	0.1	1.4	5	20	60	180
Day 91 Duodenum						
Cr in duodenum	-	-	✓	✓	✓	✓
Oxidative Changes	-	-	✓	<u>✓</u>	<u>✓</u>	<u>✓</u>
Gene Changes	-	-	<u>✓</u>	<u>✓</u>	<u>✓</u>	<u>✓</u>
Villus toxicity	-	-	-	✓	<u>✓</u>	<u>✓</u>
Crypt proliferation	-	-	-	-	✓	<u>✓</u>
Crypt DNA damage	<p><b>No Mutagenesis, No Basis for Linear Low Dose Extrapolation</b></p>					
<i>K-Ras</i> mutation (Codon 12 GAT)						

# Use of PBPK Models


# PBPK Models Can Predict Internal Dose by Intestinal Segment




Tumor Incidence in NTP Study in the Duodenum Jejunum and Ileum (male and female mice)



# PBPK Mouse Model Allows for Measures of Cr(VI) Absorption into Small Intestine Tissues



Mouse PBPK Model of GI



# Results in a More Robust Dose-Response Data Set!

Traditional Risk Assessment Relies on 6 Dose groups including controls (50 animals per dose) Drinking Water Dose

With PBPK, Drinking Water Dose Can be Converted to Internal Dose

Diff Hyperplasia in M&F Duo, Jej. & Ile

tissue	sex	flux	N	effect
dji	m&f	0	100	0
i	f	0.03	50	0
i	m	0.04	50	0
i	m	0.07	50	0
i	f	0.10	50	0
i	f	0.15	50	0
j	f	0.15	50	0
j	f	0.20	50	0
j	f	0.25	50	0
j	f	0.30	50	0
j	f	0.35	50	0
j	f	0.40	50	0
j	f	0.45	50	0
j	f	0.50	50	0
d	f	7.52	50	35
d	m	10.73	50	42
d	f	15.83	50	31
d	m	20.28	50	32
d	f	28.41	50	42



**PBPK Based Risk Assessment Allows for More Effective Use of Same Data Set**

(50 animals per dose)


- Can use males and females
- Can use each intestinal segment of each animal
- Based on Cr(VI) absorption into target tissue

# Human PBPK Model Allows for Extrapolation of Internal Dose to Humans

## Mouse PBPK Model of GI




# Model Application to Humans: Importance on Exposure Time and Diurnal Variation



*Because Cr(VI) reduction is pH-dependent, exposure events A & B will result in different internal doses even if external doses are the same*


# Model Application for Risk Assessment: Accounting for Age-Dependent Changes in Gastric pH





*The lifetime average weighted dose (a time-weighted average) is less than 2-fold greater than the adult average daily dose*

# Using Mode of Action and PBPK Models in Risk Assessment

# EPA's Draft Risk Assessment with a Mutagenic MOA Compared with That Considering The New Data




Risk Assessment



**PBPK Model**

Risk Assessment



# Risk Assessment Terms

## Point of Departure (POD)

Lower confidence level on  
10% response level


## Uncertainty Factor (UF)

3-10 Multipliers Used to Account  
for uncertainty and unaccounted  
for variability


## Reference Dose (RfD)

An RfD is defined by the U.S. EPA as “an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime.”

## Example Dose Response Curve



# Hyperplasia is Key Event Preceding Cancer (NTP 2-year Data)



Flux (absorption) of Cr(VI) into mouse small intestinal tissue for all three segments of the small Intestine

# Calculation of a Reference Dose Protective of Intestinal Cancer

$$\text{RfD} = \text{LADD} \div \text{UF}$$

Accounts for pH variability at all life stages

RfD = Reference Dose (mg/kg-day)

LADD = Lifetime Average Daily Dose (mg/kg-day) in Human

UF = Uncertainty Factors

People on Proton Pump Inhibitors have ~3-fold higher dose

\* Variations in Water Consumption can result in up to a higher dose by ~2-fold

## RfD Can Be used To Calculate a DWEL

$$\text{Drinking Water Equivalent Level (DWEL)} = (\text{RfD} \times \text{BW}) \div \text{IR}$$

DWEL = Drinking Water Equivalent Level

RfD = Reference Dose for a Lifetime exposure including sensitive subpopulations


IR = Ingestion Rate (2 L/day)

BW = Body Weight (70 kg)

**Resulting DWEL is supportive of the current MCL (~100 ppb)**

# Average Cr(VI) Detected in Drinking Water<sup>1</sup>

- Background is around 1-5 ppb
- DWEL is higher than background
- Current Standards are protective
- No risk at normal background exposures, even for sensitive subpopulations



## Summary Conclusion

- Research provides strong support for a cytotoxic MOA
  - At non-cytotoxic doses, this MOA is not operable
- This MOA is consistent with the notion that there is an exposure level that does not pose an increased cancer risk
- PBPK models are needed for risk assessment
  - Differences in internal dose between species (mice and humans)
  - Extrapolation between the high doses that caused tumors in rodents and environmentally relevant drinking water exposures
- DWEL is consistent with current Drinking Water Standards

## Questions and Discussion